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Background: Although hypertension and asthma often coexist, it is not known whether asthma in hypertensive patients predicts the occurrence of 
heart failure (HF), myocardial infarction (MI) or stroke. 
methods: Using the Myocardial Infarction Data Acquisition System (MIDAS), 759 patients were identified with a first admission for hypertension 
(ICD-9-CM [401-405]) and asthma (ICD-9-CM [493]). Three controls (n=2,277) matched for age, gender, race, and year of admission were identified 
for each case with first admission for hypertension but no concurrent or prior history of asthma. The occurrence of HF, MI and stroke was ascertained 
for 5 years follow-up. 
results: Patients with asthma (median age 50, IQR [41, 61], 69.2% women, 42.6% Blacks) had a higher risk of developing HF and the combined 
endpoint of HF, MI, stroke or death. Similar but more pronounced effects were observed among patients with non-emphysematous Chronic 
Obstructive Pulmonary Disease. 
conclusion: Hypertensive individuals with asthma have a higher risk of developing HF, the combined endpoint of HF, MI, stroke and the combined 
endpoint of HF, MI, stroke and death in 5 years follow-up compared to those without asthma. This could be related to inflammatory mediators, 
obesity and the use of beta adrenergic agonists. 
Asthmatic vs. Non-asthmatic hypertensive individuals (5 years follow-up)
N= 3036
Events #Events HR* 95% CI p-value
Stroke 91 0.77 0.43 1.37 0.3670
MI 61 0.88 0.40 1.91 0.7381
HF 313 1.60 1.22 2.11 0.0007‡
Death 241 1.10 0.80 1.50 0.5593
HF or Death (no censoring)† 576 1.24 1.00 1.54 0.0507
Combined event of HF, MI and stroke. 438 1.37 1.08 1.73 0.0081‡
Combined event of HF, MI, stroke and death. 556 1.30 1.06 1.60 0.0108‡
* Hazard ratios were adjusted for source of admission, insurance, length of stay, occurrence of diabetes, atrial fibrillation, anemia, renal disease, 
cancer, disease of the veins, and coronary artery disease during follow-up.
† Individuals are allowed to develop other cardiovascular events before HF or Death.
‡ Significant p-values.
